Summary Epilepsy remains difficult to treat with more than 30% of patients being refractory to conventional anticonvulsant therapy. Combination therapy may improve seizure control in some of these patients. Tiagabine is a new anticonvulsant that has a unique mechanism of action as a selective ␥-aminobutyric acid (GABA) re-uptake inhibitor (SGRI). Twenty consecutive patients with refractory epilepsy were treated with tiagabine, and prior to tiagabine administration the mean number of anticonvulsants that each patient had taken was five. Tiagabine therapy was initiated at a dose of 5 or 10 mg per day and was increased at weekly increments of 5 or 10 mg per day, respectively. Thirty-five percent of patients receiving tiagabine (20-40 mg per day, mean 34.29 mg per day) achieved a ≥50% reduction in seizure frequency. Tiagabine was effective when added to carbamazepine, lamotrigine, or oxcarbazepine. Tiagabine appeared more effective at higher doses. Side effects were predominately central nervous system-related, the most common being dizziness. For optimal results, tiagabine should be initiated at low doses and titrated slowly. This observational study has demonstrated tiagabine to be effective and safe in patients with refractory epilepsy.
Introduction
Around 30% of patients with epilepsy have seizures refractory to conventional anticonvulsant therapy. 1 Refractory epilepsy is extremely difficult to treat and may be associated with increased morbidity, social isolation, unemployment, and overall reduced quality of life. 2 It may also place a significant burden on health care services.
Combination therapy with new anticonvulsants can improve seizure control by ≥50% in around 30% of patients with refractory epilepsy. 3 Among the new anticonvulsants, tiagabine has a unique mechanism of action, acting as a selective ␥-aminobutyric acid (GABA) re-uptake inhibitor (SGRI). Tiagabine is recommended as adjuvant therapy in adults and children over 12 years with refractory partial seizures, with or without secondary generalisation. An integrated analysis of five multicentre, double-blind, randomised, placebo-controlled studies showed that approximately 25% of patients achieved a ≥50% reduction in refractory partial seizures after addition of tiagabine to their existing drug therapy. 4 In clinical trials involving over 3000 patients with epilepsy, tiagabine demonstrated good, predictable tolerability, which was maintained during long-term therapy. 5 Importantly, tiagabine does not affect serum concentrations of drugs, including other anticonvulsants, and does not have any clinically relevant effects on hepatic metabolism, 1 which simplifies its management as adjunctive therapy.
The Middlesborough General Hospital has a specialist epilepsy clinic, staffed by a consultant, a clinical assistant and an epilepsy specialist nurse, and treats approximately 40 patients per week. Here we report our experiences with tiagabine as adjuvant therapy in patients with refractory partial seizures.
Methods
Twenty consecutive patients with refractory partial epilepsy were treated with tiagabine between January and December 2000. Tiagabine therapy was initiated at a dose of 5 or 10 mg per day, and increased by either 5 or 10 mg per week, respectively, until maintenance doses were achieved. Patients received tiagabine two or, when the dose exceeded 30 mg, three times daily. All patients received at least one concomitant anticonvulsant, the dosage of which remained consistent throughout the treatment period.
Seizure frequency was used to evaluate the effects of tiagabine therapy, with response defined as a 50% reduction in seizure frequency compared with historical baseline (based on a retrospective review of seizure frequency charts recorded prospectively by the patient). Adverse effects were monitored and recorded.
Results
The majority of patients (85%) treated with tiagabine had refractory complex partial seizures with or without secondary generalisation ( Table 1) . The duration of their epilepsy ranged between 3 and 54 years, and prior to treatment with tiagabine the mean number of anticonvulsants that each patient had ever taken was five (range 3-9). Previous anticonvulsant therapies included: carbamazepine, valproate, lamotrigine, gabapentin, topiramate, oxcarbazepine, and phenytoin. Ten patients were initiated on tiagabine therapy at a dose of 5 mg per day and 10 patients were initiated at a dose of 10 mg per day. Patients received concomitantly at least one of the following anticonvulsants: carbamazepine, lamotrigine, valproate, phenytoin, or oxcarbazepine.
Thirty-five percent of patients who received tiagabine achieved a ≥50% reduction in seizure frequency compared to baseline (Figure 1 ). Maintenance doses ranged between 20 and 40 mg per 
day (mean 34.29 mg per day), with the majority of patients receiving 40 mg per day. One patient receiving 40 mg per day tiagabine in combination with lamotrigine experienced an 87% reduction in seizure frequency (from 30 seizures per month to four seizures per month). Another patient receiving 30 mg per day tiagabine in combination with carbamazepine experienced a 90% reduction in seizure frequency (from 10 seizures per month to 1 seizure per month). Two patients initiated at 5 mg per day experienced dizziness during titration; however, tolerability improved after a few weeks of treatment, and both patients were maintained on 30 mg per day. Side effects experienced by patients were mostly central nervous system related and included dizziness (9 patients), tiredness (5 patients), and ataxia (1 patient). All side effects resolved upon dose modification or withdrawal of tiagabine.
Discussion
Refractory epilepsy is notoriously difficult to treat. In this study, 35% of patients with refractory partial seizures responded to adjunctive therapy with tiagabine; a response rate similar to that observed in randomised controlled trials with tiagabine and other new anticonvulsants. 3 The efficacy of tiagabine was evidenced most clearly in one patient who achieved seizure control on tiagabine when previously they had experienced frequent (4-20 per day) partial seizures with secondary generalisation over a twenty-year period despite treatment with combinations of valproate, carbamazepine, phenytoin, phenobarbitone, vigabatrin, lamotrigine, gabapentin, topiramate, clobazam and acetazolamide.
Patients responding to tiagabine received maintenances doses of 20-40 mg per day, which is consistent with the recommended doses of 15-30 mg per day in patients taking concomitant non-enzyme-inducing-drugs and 30-45 mg per day in patients taking at least one enzyme-inducing anticonvulsant. Tiagabine therapy appeared more efficacious at higher dosages, with around 60% of the patients receiving 40 mg per day achieving a ≥50% reduction in seizures. This result is consistent with other studies that have reported a significant dose-response relationship with tiagabine. 4 Tiagabine appeared well-tolerated, with the adverse events observed being consistent with those commonly reported. Side effects are often observed during initial titration of tiagabine and are more common during twice daily dosing than during three-or four-times-daily regimens. 6 This study highlights the importance of slow dose titration with tiagabine, as one patient who experienced dizziness initially, later achieved seizure control with tiagabine after following a more gradual titration schedule.
It has been suggested that tiagabine may be particularly beneficial to patients that have previously failed to respond to treatment with sodium channel blockers, patients with a history of cutaneous reactions to other drugs, patients with mild to moderate epilepsy, patients receiving valproate or other non-enzyme inducing anticonvulsants, and patients where it is particularly important to avoid cognitive impairment. 7 In this study, patients receiving concomitant carbamazepine, lamotrigine or oxcarbazepine had improved seizure control with tiagabine.
Conclusions
This observational study of tiagabine in clinical practice has demonstrated it to be effective and safe for patients with refractory epilepsy. In combination with an antiepileptic treatment considered ineffective, tiagabine reduced the frequency of seizures by at least 50% in around 1/3 of patients treated. The efficacy of tiagabine was comparable to that seen in randomised controlled trials with tiagabine and other new anticonvulsants. In order to achieve optimal results, tiagabine therapy should be initiated at a low dose and increased slowly.
